18 research outputs found
Factors associated with select IOM-defined care indicators, DC Cohort, 2011–2016<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup>.
<p>Factors associated with select IOM-defined care indicators, DC Cohort, 2011–2016<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186036#t004fn001" target="_blank"><sup>a</sup></a><sup>,</sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186036#t004fn002" target="_blank"><sup>b</sup></a><sup>,</sup><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186036#t004fn003" target="_blank"><sup>c</sup></a>.</p
HHS and IOM quality of care indicators assessed using DC Cohort study data<sup>a</sup>.
<p>HHS and IOM quality of care indicators assessed using DC Cohort study data<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0186036#t001fn001" target="_blank"><sup>a</sup></a>.</p
Proportion of DC cohort participants meeting criteria for selected HHS and IOM indicators for quality of care, DC cohort, 2011–2016.
<p>This figure represents individuals who were enrolled in the DC Cohort as of September 30, 2016 and met the criteria for selected Department of Health and Human Services and Institute of Medicine HIV quality of care indicators. While high proportions of participants met the HIV-related indicators (69%-95%), screening for sexually transmitted infections was relatively low (26%-51%).</p
Risk factors for HIV infection among MSM in univariate and multivariate analyses, 1998–2002.
<p>NOTE. Multivariate model controlled for race, treatment arm assignment, date of study entry, education level, and geographic region. CI, confidence interval; HR, hazards ratio; UAI, unprotected anal intercourse.</p
US MSM HIV seroincidence (per 100 person-years) by participant demographic and behavioral characteristics at enrollment (n = 4684).
<p>NOTE: Not all columns add up to 4684 due to non-response. SC, seroconverters; UAI, unprotected anal intercourse.</p
Preference for long-acting injectable versus daily oral PrEP among men who have sex with men (n = 313).
<p>One participant who did not know his preference was excluded.</p
Willingness to use long-acting injectable PrEP among men who have sex with men (n = 313).
<p>One participant who did not know his willingness was excluded.</p
Correlates of preferring long-acting injectable PrEP to daily oral PrEP among men who have sex with men who had a preference for PrEP modality (n = 284).
<p>Correlates of preferring long-acting injectable PrEP to daily oral PrEP among men who have sex with men who had a preference for PrEP modality (n = 284).</p
HIV incidence among MSM study participants in the United States, by city, 1998–2002*.
<p>HIV incidence among MSM study participants in the United States, by city, 1998–2002*.</p
Descriptive characteristics and correlates of being very likely to use long-acting injectable PrEP among men who have sex with men recruited for NHBS in Washington, DC who self-reported HIV-negative or unknown status, 2014 (n = 314).
<p>Descriptive characteristics and correlates of being very likely to use long-acting injectable PrEP among men who have sex with men recruited for NHBS in Washington, DC who self-reported HIV-negative or unknown status, 2014 (n = 314).</p